The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Solution Conformations Shed Light on PROTAC Cell Permeability
Open accessAbstract
Proteolysis targeting chimeras (PROTACs) induce intracellular degradation of target proteins. Their bifunctional structure puts degraders in a chemical space where ADME properties often complicate drug discovery. Herein we provide the first structural insight into PROTAC cell permeability obtained by NMR studies of a VHL-based PROTAC (1), which is cell permeable despite having a high molecular weight and polarity and a large number of rotatable bonds. We found that 1 populates elongated and polar conformations in solutions that mimic extra- and intracellular compartments. Conformations were folded and had a smaller polar surface area in chloroform, mimicking a cell membrane interior. Formation of intramolecular and nonclassical hydrogen bonds, π–π interactions, and shielding of amide groups from solvent all facilitate cell permeability by minimization of size and polarity. We conclude that molecular chameleonicity appears to be of major importance for 1 to enter into target cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The linker can contribute to the PROTAC solution conformation68 and degradation efficiency (DC50/Dmax)69, and influence the E3 ligase–POI interactions and presentation of the POI within the zone of ubiquitylation (Fig. 5).”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Self-citationEdmondson, S. D., Yang, B., & Fallan, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.030 · Cited by 422
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection
DeGoey, D. A., Chen, H.-J., Cox, P. B., & Wendt, M. D. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00717 · Cited by 390
Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs
Whitty, A., Zhong, M., Viarengo‐Baker, L. A., Beglov, D., Hall, D. R., & Vajda, S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.005 · Cited by 291
Cited by
Sorted by citations
Items 101–200 of 214
Venturi, A., Bona, S. D., Desantis, J., Eleuteri, M., Bartalucci, M., Baroni, M., Benedetti, P., Goracci, L., & Cruciani, G. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01235 · Cited by 13
Crystallizing the Uncrystallizable: Insights from Extensive Screening of PROTACs
Screen, M. A., McCabe, J. F., Askin, S., Guest, J. L., Hodgkinson, P., Cabeza, A. J. C., Blundell, T. J., Rainer, D. N., Coles, S. J., Longcake, A., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07977 · Cited by 11
Bifunctional robots inducing targeted protein degradation
Sobhia, M. E., Kumar, H., & Kumari, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115384 · Cited by 11
Nuclear magnetic resonance free ligand conformations and atomic resolution dynamics
Balazs, A., Davies, N. L., Longmire, D., Packer, M. J., & Chiarparin, E. (2021) · Magnetic Resonance · doi:10.5194/mr-2-489-2021 · Cited by 11
Yang, Y., Zhao, C.-J., Jin, Z.-F., Zheng, J., & Ma, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1120828 · Cited by 11
Castellani, B., Eleuteri, M., Bona, S. D., Cruciani, G., Desantis, J., & Goracci, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01144 · Cited by 10
Zhao, C., Wang, H., Zhan, W., Lv, X., & Ma, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00079 · Cited by 9
Inganäs, E., Lavén, H., Caraballo, R., Klingegård, F., Eklund, M., Andersson, L., Hilgendorf, C., & Matsson, P. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01499 · Cited by 9
Strategies for Post-Translational Control of Protein Expression and Their Applications
Utsugi, Y., & Miyamae, Y. (2021) · Applied Sciences · doi:10.3390/app11188300 · Cited by 9
Peng, R., Liu, X., Chen, C., Guo, R., & Min, J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00961d · Cited by 8
Data-Driven Design of PROTAC Linkers to Improve PROTAC Cell Membrane Permeability
Murakami, Y., Ishida, S., Cho, N., Yuki, H., Ohta, M., Honma, T., Demizu, Y., & Terayama, K. (2026) · JACS Au · doi:10.1021/jacsau.6c00033 · Cited by 10
Reviewing the toolbox for degrader development in oncology
Cresser-Brown, J. O., Marsh, G. P., & Maple, H. J. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.04.009 · Cited by 8
The rise of targeting chimeras (TACs): next-generation medicines that preempt cellular events
Hollingsworth, S. A., Johnson, S. A., Khakbaz, P., Meng, Y., Mouchlis, V. D., Pierce, O., Prytkova, V. D., Vik, E. S., Weiss, D. R., & Shanmugasundaram, V. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03104-z · Cited by 11
Explainable Machine Learning for ETR and Drug Chameleonicity
Price, E., Dagommer, M., Thieme, M., Hong, R. S., Kalvass, J. C., Doktor, S. Z., Rivkin, A., Wang, Y.-T., Cox, P. B., Pandey, A., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00536 · Cited by 7
Sowndharya, M., Joga, R., Gandhi, K., Yerram, S., Raghuvanshi, R. S., & Srivastava, S. (2024) · Pharmaceutical Patent Analyst · doi:10.1080/20468954.2025.2500809 · Cited by 7
Developing Multi-Component Solid Formulation Strategies for PROTAC Dissolution Enhancement
Screen, M. A., Askin, S., McCabe, J. F., Jacobs, E., Anane‐Adjei, A. B., Mahon, C. S., Wilson, M. R., & Steed, J. W. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01107 · Cited by 7
Rastelli, E. J., Sannino, S., Hart, D. J., Sharlow, E. R., Lazo, J. S., Brodsky, J. L., & Wipf, P. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128167 · Cited by 7
Novel advances in biotransformation and bioactivation research – 2020 year in review
Khojasteh, S. C., Argikar, U. A., Driscoll, J. P., Heck, C. J. S., King, L. M., Jackson, K. D., Jian, W., Kalgutkar, A. S. S., Miller, G. P., Kramlinger, V. M., et al. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1916028 · Cited by 8
Kamioka, S., Ito, R., Ohshimo, K., & Misaizu, F. (2025) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.5c01573 · Cited by 9
Evaluation of Oral PROTAC Guidelines: Efflux Ratio Outweighs Chameleonicity Descriptors
Manach, C. L., Viklund, J., Kwapień, K., & Winiwarter, S. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00043 · Cited by 6
Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders
Crowe, C., & Ciulli, A. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00800 · Cited by 6
Linkerology in PROTACs: learnings for proximity-inducing therapeutics
Prieto‐Díaz, R., Urbina, A., Rodriguez-Rios, M., & Ciulli, A. (2026) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2026.07.004 · Cited by 7
Amide-to-ester substitution as a strategy for optimizing PROTAC permeability and cellular activityPreprint
Klein, V. G., Bond, A. G., Craigon, C., Lokey, R. S., & Ciulli, A. (2021) · doi:10.33774/chemrxiv-2021-47tqn · Cited by 6
PROTACs in targeted protein degradation: Advances in development and AI-enhanced drug discovery
Du, M., Liu, T., Wang, W., Fan, S., Tian, M., Du, Q., Wang, Z., Li, X., Liu, X., Xia, Q., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100332 · Cited by 4
Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
Knoll, N., Neamati, N., & Üren, A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00730 · Cited by 5
Bhusal, S., & Valsson, Ó. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp02530c · Cited by 4
Computational Modeling of PROTAC Ternary Complexes and Linker Design
Miller, S. A., Andrianov, G. V., Mischley, V., Wharton, K. A., Chen, J. J., & Karanicolas, J. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch5 · Cited by 4
On-demand modular assembly for expedited PROTAC development
Mukherjee, A., Kadam, V. D., Miao, Q., Zhang, W., MacKenzie, K. R., Tan, Z., & Teng, M. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2364637 · Cited by 4
Advances in light-activated PROTACs and phototherapy-combined approaches for cancer treatment
Zhang, W., Li, S., Yuan, H., & Zhao, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118310 · Cited by 3
Wang, X., Meng, R.-J., Cao, W.-J., Cheng, L., Zhang, J., & Chen, S. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118473 · Cited by 4
Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems
Yao, T., Zhou, Z., Wang, G., Zhu, Z.-Y., & Li, X.-N. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01853-2 · Cited by 5
Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD)
Banerjee, M., Detappe, A., & Lammers, T. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115922 · Cited by 4
Rahman, M. K., Marzullo, B. P., Holman, S. W., Barrow, M. P., Ray, A. D., & O’Connor, P. B. (2024) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.3c00342 · Cited by 4
Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity
Cheng‐Sánchez, I., Gosselé, K. A., Palaferri, L., Laul, E., Riccabella, G., Bedi, R. K., Li, Y., Müller, A., Corbeski, I., Caflisch, A., et al. (2024) · JACS Au · doi:10.1021/jacsau.4c00292 · Cited by 5
Pharmacology of PROTAC Degrader Molecules
Pike, A., Guzzetti, S., Gutierrez, P. M., & Scott, J. S. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch11 · Cited by 3
Getting bifunctional molecules into cells
Lokey, R. S., & Pye, C. R. (2022) · Science · doi:10.1126/science.adf4412 · Cited by 3
Plesniak, M. P., Taylor, E. K., Eisele, F., Kourra, C. M. B. K., Michaelides, I. N., Oram, A., Wernevik, J., Valencia, Z. S., Rowbottom, H., Mann, N., et al. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-dz9l7 · Cited by 3
Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader
Orsi, D. L., Lazarski, K. E., Improgo, R., Agafonov, R. V., Ahn, J. Y., Baddour, J., Cassidy, K. B., Chaturvedi, P., Cole, K. S., Deibler, R. W., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00337g · Cited by 2
Essa, K., Zacarı́as, N. V. O., Röth, S., Xin, B., de Winter, S., van der Horst, C., Bleijs, B. T. M., de Heiden, R. A., Voulgaraki, R., Neubert, E., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02920 · Cited by 3
Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs
Hu, L., Wu, S., Wang, W., He, H., Che, J., Wu, M., & Dong, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118499 · Cited by 4
Abdelwahid, M. A. S., Hayakawa, E., Hirai, K., Ishii, M., Kanamitsu, K., Yasuda, S., Ohtake, F., Sato, S., Tomoshige, S., & Ishikawa, M. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02791 · Cited by 4
Tian, L., Zhang, B., Zhang, B., Hu, J., Ke, C., Zhang, Y., Zhou, J., Xiong, H., Xia, J., Nan, J., et al. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c01027 · Cited by 2
Targeted Protein Degradation and Delivery Strategies in the Context of Neurological Disorders
Lu, H., Yang, Z., Kayumov, M., Wang, Y., Tang, F., Wang, X., Xia, T., Lei, T., Tong, F., & Gao, H. (2026) · ACS Nano · doi:10.1021/acsnano.6c04420 · Cited by 3
Lu, X., Qin, J., Dong, S., Yuan, Y., Zhang, Z., Zhang, B., Chen, X., Gan, X., Liang, H., & Liu, F. (2026) · Biomarker Research · doi:10.1186/s40364-026-00937-9 · Cited by 3
Kamioka, S., Xuan, K. V., Hirata, K., Ito, R., Ohshimo, K., Lisy, J. M., Fujii, M., Ishiuchi, S., & Misaizu, F. (2026) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.6c01360 · Cited by 2
Enabling formulations for PROTACs: A line-of-sight to clinic
Swedrowska, M., Fransson, R., Jacobs, E., Abouselo, A., Nash, S., Singhal, M., & Carlert, S. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115927 · Cited by 2
The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer
Lin, X., Xiang, H., & Luo, G. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104772 · Cited by 4
NMR Spectroscopy for Studying Peptide Conformations and Cell Permeability
Adaligil, E., & Fairbrother, W. J. (2022) · ACS symposium series · doi:10.1021/bk-2022-1417.ch006 · Cited by 2
Application of PROTAC Technology in Drug Development
Kharkar, P. S., & Jadhav, A. L. (2022) · Methods and principles in medicinal chemistry · doi:10.1002/9783527827855.ch10 · Cited by 2
Structure-based Design of CBP/EP300 Degraders: When Coopera-tivity Overcomes AffinityPreprint
Cheng‐Sánchez, I., Gosselé, K. A., Palaferri, L., Laul, E., Riccabella, G., Bedi, R. K., Li, Y., Müller, A., Caflisch, A., & Nevado, C. (2024) · ChemRxiv · doi:10.26434/chemrxiv-2024-7w489 · Cited by 2
Targeted Protein Degraders- The Druggability Perspective
Singh, S., & Srivastava, P. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.023 · Cited by 1
Cornu, M., Lemaitre, T., Schwalen, F., Kieffer, C., & Voisin‐Chiret, A. S. (2024) · Biologie Aujourd hui · doi:10.1051/jbio/2024010 · Cited by 1
Computational approaches to aid PROTAC drug discovery
Chakraborti, S., & McAulay, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00004-2 · Cited by 1
Coderch, C., Bazán, H. A., Bazan, N. G., Bhattacharjee, S., Álvarez‐Buílla, J., & de Pascual‐Teresa, B. (2025) · ChemMedChem · doi:10.1002/cmdc.202500639 · Cited by 1
Kim, B., Sheridan, R. P., Zhang, R., de Barros, E. P., Johnston, J. M., & Li, X. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01600 · Cited by 2
Conformation-Dependent Complexation Interactions for a SMARCA2 PROTAC and Cyclodextrin
Laramy, M. N. O., Napolitano, J. G., Zhou, Y., Russell, D. J., Robinson, S., Khirich, G., & Gobbi, A. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01600 · Cited by 1
Rox, K. (2026) · ChemMedChem · doi:10.1002/cmdc.202500743 · Cited by 1
Engstrom, A., Vasta, J. D., Robers, M. B., & Lokey, R. S. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00871 · Cited by 1
Brenner, C., Cui, Y., Schmidt, D., Kirchmair, J., Tan, L., & Braun, N. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01908 · Cited by 1
Liu, M., Song, Y., Luo, K., Zhao, Y., & Zhang, H. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105430 · Cited by 2
Laul, E., Gosselé, K. A., Matter, C. M., Liu, W.-H. W., González, J. A., Holland, J. P., Caflisch, A., & Nevado, C. (2026) · JACS Au · doi:10.1021/jacsau.6c00397 · Cited by 1
Context matters in PROTAC design: navigating the trade-off between degradation and developability
Zhang, B., Zhang, Y., Zhang, B., Hu, J., Ke, C., Wu, T., Wei, M., Xia, J., Wang, M., Zhao, Q., et al. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2707656 · Cited by 1
A Different Kind of Restraint Suitable for Molecular Dynamics SimulationsPreprint
Kolossváry, I., & Sherman, W. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.27.505552 · Cited by 1
WITHDRAWN: Targeted protein degradation: A promising approach for cancer treatment
Khan, M. Z. I., Nazli, A., Naz, I., Khan, D., Haq, I., & Chen, J. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.09.004 · Cited by 1
RetractedProteolysis‐Targeting Chimeras (PROTACs)
Shen, L. (2025) · doi:10.1002/9781394300150.ch1 · Cited by 1
Balazs, A. (2021) · Magnetic Resonance · doi:10.5194/mr-2021-27-ac2
Balazs, A. (2021) · Magnetic Resonance · doi:10.5194/mr-2021-27-ac1
(2021) · Magnetic Resonance · doi:10.5194/mr-2021-27-rc2
(2021) · Magnetic Resonance · doi:10.5194/mr-2021-27-rc1
Kjølbye, L. R., Pereira, G. P., Bartocci, A., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16.pr5
Destruction with a Purpose: Targeted Protein Degradation in Drug Discovery
Martinelli, P., Kofink, C. C., Boeck, G., Weinstabl, H., & Koegl, M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch11
Taming the Beast: How to Optimize DMPK–PD Properties of Oral Degraders
Rynn, C., Vyver, A. J. V. D., Walz, A., Cantrill, C., & Wittwer, M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch12
PROTAC ® Protein Degraders: Bridging the Divide from Chemical Biology Tools to Clinical Candidates
Araujo, E. M. V., & Hornberger, K. R. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch13
Kjølbye, L. R., Pereira, G. P., Bartocci, A., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16.pr4
Review: Towards design of drugs and delivery systems with the Martini coarse-grained model — R0/PR1
Kjølbye, L. R., Pereira, G. P., Bartocci, A., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16.pr1
Review: Towards design of drugs and delivery systems with the Martini coarse-grained model — R0/PR3
Kjølbye, L. R., Pereira, G. P., Bartocci, A., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16.pr3
Review: Towards design of drugs and delivery systems with the Martini coarse-grained model — R0/PR2
Kjølbye, L. R., Pereira, G. P., Bartocci, A., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16.pr2
New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery
Valeur, E. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00911
Clinical Development of PROTACs
Dubey, A., Pal, K., & Gota, V. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_9
Targeting methylation and acetylation in colon cancer
Gopathy, S., Lakshmanan, D., AROCKYASAMY, A. S., Srividya, S., & Bhavani, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27765-8.00006-0
Ligand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4
Kotlarek, D., Dudek, K., Woźniak, B., Pastok, M. W., Shishov, D. V., Cottens, S., Biśta, M., Krzywiecka, E., Górecka, K. M., Jurczak, K., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.202500849
Fusion Molecules Between the STAT5b Inhibitor Stafib‐2‐CR and a Cereblon Ligand
Münzel, T., Seidenstücker, K. C., Protzel, C., Berg, A., & Berg, T. (2026) · ChemistryOpen · doi:10.1002/open.202600007
Emerging cellular uptake mechanisms of bRo5 PROTACs
Tashima, T. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00243a
Contemporary Applications of Chemical Libraries for Drug Discovery and Methods for Their Synthesis
Hansen, T. N., & Hansen, N. J. V. (2026) · ChemistryEurope · doi:10.1002/ceur.70283
Leveraging AI and structural proteomics for rational design of a KAT6A degraderPreprint
Arad, G., Simchi, N., Brodsky, S., Shtrikman, A., Kedem, Y., Alchanati, I., Otonin, G., Shenoy, A., Kovalerchik, D., Shchory, M. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.25.727609
Atomic degradation: chemical design strategies and immunotherapeutic mechanisms of radio-PROTACs
Varol, T. Ö., & Varol, M. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-026-02254-5
Jaki, M., Köll-Weber, M., Lembeck, J., Wittmann, M., & Süss, R. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100627
Flexible molecular chameleons: structural adaptability and therapeutic applications
Bose, D., Bhardwaj, P., & Girigoswami, A. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1886764
Kamioka, S., Ito, R., Ohshimo, K., & Misaizu, F. (2026) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.6c02049
Fathizadeh, A., Araujo, E. M. V., Cockroft, N. T., Beno, B. R., & Hornberger, K. R. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00305
Ni, X., Li, M., Tang, J., Qi, Z., Zhou, Y., Liao, Z., Song, Y., Miao, Q., Zhang, Z., Jiang, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01893
Jalalypour, F., & Mercado, R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.05.756765
More, R., Sanka, K., & Kuttiappan, A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.109004
Zhang, W., Li, S., Yao, Y., Mao, Y., Jiang, W., & Li, S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.109664
Jaki, M., Dari, L., Köll-Weber, M., Hermann, A., Wenzel, C., Pollak, A., Lembeck, J., Kaul, L., Balzer, B. N., Wittmann, M., et al. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107686
Wang, T., Ji, C., & Zhao, T. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1967704
BindingDB (2023) · UC San Diego · doi:10.7270/q2vm4h9b
Metadata
- Authors
- Atilaw, Y., Poongavanam, V., Svensson Nilsson, C., Nguyen, D., Giese, A., Meibom, D., Erdelyi, M., & Kihlberg, J.
- Affiliations
- Uppsala University (SE)
- Uppsala University , , ,
- Nuvisan (Germany) (DE)
- Bayer (Germany) (DE)
- Corresponding author
- Kihlberg, Jan
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-25
- Volume
- 12
- Issue
- 1
- Pages
- 107-114
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC7812666
- OpenAlex
- W3117557114
- Cited by
- 208
- References
- 33
- Citations by year
- 2026: 39 · 2025: 33 · 2024: 40 · 2023: 35 · 2022: 37 · 2021: 24
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- Funders
- Bayer (NA)
- Vetenskapsrådet (2016-03602, 2016-05160)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- PROTACs, membrane permeability, solution conformation, polar surface area, hydrogen bonding, π-π stacking, intracellular protein degradation, ADME properties
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
